Meclofenamate Sodium in Treating Patients with Recurrent or Progressive Brain Metastasis from Solid Tumors

Inclusion Criteria

• Karnofsky performance status (KPS) >= 60
• At least one recurrent or progressive brain metastasis(es) from any solid primary tumor that is visible on magnetic resonance imaging (MRI) as assessed by the patient’s treating physician
• Recurrence may occur after any treatment: recurrence after whole-brain radiation, stereotactic radiosurgery, surgical resection, systemic chemotherapy are all acceptable
• There is no limit on the number of brain metastases
• Surgical resection or stereotactic radiosurgery (SRS) to other recurrent lesions in the same patient are acceptable, provided one recurrent lesion remains untreated
• Systemic disease must be well-controlled or no evidence of disease (NED) in the opinion of the patient’s primary oncologist

Exclusion Criteria

• Inability to get brain MRI +/- contrast
• Progressive systemic disease
• Known leptomeningeal metastases
• Primary brain tumor
• Active intracranial hemorrhage
• Surgery less than two weeks before enrollment
• Gastrointestinal (GI) hemorrhage (active or in recent 6 months)
• Concurrent anti-platelet therapy
• Concurrent anti-coagulation therapy
• Active bleeding diathesis
• Platelet count =< 70,000/mm^3
• International normalized ratio (INR) > 1.6 and a partial thromboplastin time (PTT) > 40 seconds
• Serum creatinine > 2 mg/dL OR creatinine clearance level (CrCL) < 30ml/min
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/L
• Hemoglobin < 8 g/dL
• Allergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)
• Inability to tolerate PO dosing
• Steroid dose increased in the most recent two weeks
• Pregnancy
• Cardiac arrhythmia requiring medical management and/or pacemaker
• Known congestive heart failure requiring medical management